<code id='66236A943C'></code><style id='66236A943C'></style>
    • <acronym id='66236A943C'></acronym>
      <center id='66236A943C'><center id='66236A943C'><tfoot id='66236A943C'></tfoot></center><abbr id='66236A943C'><dir id='66236A943C'><tfoot id='66236A943C'></tfoot><noframes id='66236A943C'>

    • <optgroup id='66236A943C'><strike id='66236A943C'><sup id='66236A943C'></sup></strike><code id='66236A943C'></code></optgroup>
        1. <b id='66236A943C'><label id='66236A943C'><select id='66236A943C'><dt id='66236A943C'><span id='66236A943C'></span></dt></select></label></b><u id='66236A943C'></u>
          <i id='66236A943C'><strike id='66236A943C'><tt id='66236A943C'><pre id='66236A943C'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:77817
          Checkpoint inhibitor
          Adobe

          ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

          The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

          advertisement

          iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Continuity nursing helped my family in our darkest PICU moments
          Continuity nursing helped my family in our darkest PICU moments

          EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

          read more
          Merus drug and Keytruda shrank tumors in patients with head and neck cancer
          Merus drug and Keytruda shrank tumors in patients with head and neck cancer

          ThisimmunofluorescenceimageshowsTcells(ingreenandyellow)inthemicroenvironmentofaheadandnecksquamousc

          read more
          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more

          Do more moles mean more problems? Not so, says new study

          Thenumberofmolesisnotagoodindicatorofcancer'saggressiveness.APStockDermatologistsconstantlyhammerhom